Gene for recognizing tumor cells and inducing pyroptosis of tumor cells, recombinant vector, recombinant virus and application thereof

Through the artificial promoter and three-input logic gate system combined with the UAS-NT-GSDM gene, specific recognition and pyroptosis induction of tumor cells are achieved, and the specificity and efficiency of identifying and inducing pyroptosis in the prior art are solved. The problem of low significantly inhibits tumor development and activates anti-tumor immunity.

CN118931897AActive Publication Date: 2024-11-12SUN YAT SEN UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202410847879.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-12
Estimated Expiration
2044-06-27

AI Technical Summary

Technical Problem

The prior art has problems of poor specificity, low efficiency and high cost in identifying and inducing tumor cell pyroptosis, making it difficult to effectively distinguish between normal cells and tumor cells, and lacks effective anti-tumor immune activation methods.

Method used

A recombinant vector and recombinant virus system were developed, using artificial promoters pETV4, pSurvivin and pTP53 to bind the EGFP gene, and through a three-input logic gate system (Gal4-int1, int2-VP64-NLS-FUS and int2-KRAB-NLS) and The UAS-NT-GSDM gene realizes specific recognition and pyroptosis induction of tumor cells, and promotes anti-tumor immune response.

Benefits of technology

It has achieved efficient distinction between tumor cells and normal cells, significantly inhibited tumor development, activated anti-tumor immunity, had high safety and few side effects, and could target the killing of tumor cells and prevent recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004916127410000011
    Figure HDA0004916127410000011
  • Figure HDA0004916127410000021
    Figure HDA0004916127410000021
  • Figure HDA0004916127410000031
    Figure HDA0004916127410000031
Patent Text Reader

Abstract

The invention provides an artificial promoter capable of distinguishing normal cells from tumor cells, a gene, a recombinant vector, a recombinant virus and application of the artificial promoter. The artificial promoter comprises at least one of pETV4, pSurvivin and pTP53; the sequence of the pETV4 is as shown in SEQ ID NO: 2, the sequence of the pSurvivin is as shown in SEQ ID NO: 3, and the sequence of the pTP53 is as shown in SEQ ID NO: 4. The invention also provides a gene for identifying tumor cells and inducing pyroptosis thereof, a recombinant vector, a recombinant virus and application thereof, the gene is delivered to tissue cells of a host through the vector, NT-GSDMD is selectively expressed in the tumor cells to induce pyroptosis, anti-tumor immunity is activated at the same time, the purpose of effectively inhibiting tumor generation and development is achieved, and the application of the gene to tumor cells is promoted. The effect is very obvious.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a recombinant vector and recombinant virus that recognizes tumor cells and induces their pyroptosis, and their applications. Background Art

[0002] The occurrence and progression of tumors are regulated by complex multi-gene networks; therefore, the therapeutic effects of targeting a single gene are often limited. Artificial gene circuits (artificial gene products) possess the ability to simultaneously recognize multiple abnormal molecular signals within cells. These signals are processed through logic gates, ultimately selectively producing regulatory or therapeutic effects in tumor cells. Due to their high specificity, programmability, and dynamic regulation, gene circuits (gene products) are gradually becoming important tools for precision diagnosis and treatment of tumors.

[0003] Pyroptosis is an inflammatory cell death process characterized by cell swelling, membrane rupture, and the release of immunostimulants triggered by the N-terminal domain (NT-GSDM) of the GSDM protein forming pores in the cell membrane. Pyroptosis can not only effectively kill tumor cells but also induce a strong anti-tumor immune response, demonstrating great promise for applications in cancer therapy.

[0004] Specific delivery of NT-GSDM into tumor cells is crucial for pyroptosis-inducing therapy. Current therapies suffer from poor specificity, low efficiency, and high cost. To address these issues, this application develops a gene pathway that automatically identifies and induces pyroptosis in tumor cells. Delivered in vivo via viral or non-viral vectors, it selectively expresses NT-GSDM in tumor cells to induce pyroptosis while simultaneously promoting anti-tumor immunity, effectively inhibiting tumor development. Summary of the Invention

[0005] The purpose of this invention is to provide an artificial promoter, gene, recombinant vector, and recombinant virus that can distinguish between normal cells and tumor cells, and their applications. This invention also provides a gene, recombinant vector, and recombinant virus that can identify tumor cells and induce their pyroptosis, and their applications.

[0006] To achieve the above objectives, the technical solution adopted is as follows: an artificial promoter that can distinguish between normal cells and tumor cells, wherein the artificial promoter includes at least one of pETV4, pSurvivin and pTP53; the sequence of pETV4 is shown in SEQ ID NO:2, the sequence of pSurvivin is shown in SEQ ID NO:3, and the sequence of pTP53 is shown in SEQ ID NO:4.

[0007] This invention provides a gene that can distinguish between normal cells and tumor cells, the gene comprising at least one of the pETV4-EGFP gene, the pSurvivin-EGFP gene, and the pTP53-EGFP gene; the sequence of the pETV4-EGFP gene is shown in SEQ ID NO:5, the sequence of the pSurvivin-EGFP gene is shown in SEQ ID NO:6, and the sequence of the pTP53-EGFP gene is shown in SEQ ID NO:7.

[0008] This invention provides a recombinant vector capable of distinguishing between normal cells and tumor cells. The recombinant vector comprises at least one of the following: a recombinant plasmid containing the pETV4-EGFP gene, a recombinant plasmid containing the pSurvivin-EGFP gene, and a recombinant plasmid containing the pTP53-EGFP gene. The sequence of the pETV4-EGFP gene is shown in SEQ ID NO:5, the sequence of the pSurvivin-EGFP gene is shown in SEQ ID NO:6, and the sequence of the pTP53-EGFP gene is shown in SEQ ID NO:7. Preferably, the base vectors of the recombinant plasmids containing the pETV4-EGFP gene, the pSurvivin-EGFP gene, and the pTP53-EGFP gene are all viral vectors. Preferably, the base vectors of the recombinant plasmids containing the pETV4-EGFP gene, the pSurvivin-EGFP gene, and the pTP53-EGFP gene are all pCDH plasmids.

[0009] This invention provides a recombinant virus that can distinguish between normal cells and tumor cells. The recombinant virus is a packaged body obtained by co-transfecting host cells with the above-described recombinant vector and an auxiliary packaging plasmid.

[0010] Preferably, the host cell is a 293T cell.

[0011] This invention provides the application of the artificial promoter, gene, recombinant vector, and recombinant virus described above in the preparation of reagents or kits for distinguishing between normal cells and tumor cells.

[0012] This invention provides a gene for recognizing tumor cells and inducing their pyroptosis, the gene comprising the pETV4-Gal4-int1 gene, the pSurvivin-int2-VP64-NLS-FUS gene, the pTP53-int2-KRAB-NLS gene, and the UAS-NT-GSDM gene; the sequences of the pETV4-Gal4-int1 gene, the pSurvivin-int2-VP64-NLS-FUS gene, and the pTP53-int2-KRAB-NLS gene are shown in SEQ ID NO:12, SEQ ID NO:21, and SEQ ID NO:25, respectively; preferably, the sequence of the NT-GSDM gene in the UAS-NT-GSDM gene is shown in SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:39. As shown in NO:40; more preferably, the UAS-NT-GSDM gene is the UAS-NT-GSDMD gene, and the sequence of the UAS-NT-GSDMD gene is shown in SEQ ID NO:41.

[0013] This invention provides a recombinant vector for recognizing tumor cells and inducing their pyroptosis. The recombinant vector comprises a recombinant plasmid 1 containing the pETV4-Gal4-int1 gene, the pSurvivin-int2-VP64-NLS-FUS gene, and the pTP53-int2-KRAB-NLS gene, and a recombinant plasmid 2 containing the UAS-NT-GSDM gene. The sequences of the pETV4-Gal4-int1 gene, the pSurvivin-int2-VP64-NLS-FUS gene, and the pTP53-int2-KRAB-NLS gene are shown in SEQ ID NO:12, SEQ ID NO:21, and SEQ ID NO:25, respectively. Preferably, the sequence of the NT-GSDM gene in the UAS-NT-GSDM gene is shown in SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:35. As shown in NO:40; more preferably, the UAS-NT-GSDM gene is the UAS-NT-GSDMD gene, the sequence of the UAS-NT-GSDMD gene is shown in SEQ ID NO:41, and the base vectors of recombinant plasmid 1 and recombinant plasmid 2 are viral vectors, respectively. Preferably, the base vectors of recombinant plasmid 1 and recombinant plasmid 2 are pCDH plasmids, respectively.

[0014] The present invention provides a recombinant virus that recognizes tumor cells and induces their pyroptosis. The recombinant virus is a packaged body obtained by co-transfecting host cells with the above-described recombinant vector and an auxiliary packaging plasmid.

[0015] Preferably, the host cell is a 293T cell. Preferably, the helper packaging plasmids include psPAX2 and pMD2.G.

[0016] This invention provides the application of the artificial promoter, gene, recombinant vector, or recombinant virus described above in the preparation of drugs that recognize tumor cells and induce their pyroptosis.

[0017] Beneficial effects:

[0018] This application provides a gene that automatically identifies and induces pyroptosis in tumor cells. This gene is delivered to the host's tissue cells via a vector. It senses the expression of ETV4, Survivin, and TP53 in the cells through an artificial promoter. Then, it distinguishes between normal cells and tumor cells through a three-input logic gate system composed of fusion proteins Gal4-int1, int2-VP64-NLS-FUS, and int2-KRAB-NLS. Finally, it selectively expresses NT-GSDMD in tumor cells to induce pyroptosis and activate anti-tumor immunity, thereby effectively inhibiting the occurrence and development of tumors. The effect is very significant.

[0019] Advantages of the gene product applied for:

[0020] a. Safe and with few side effects: It distinguishes between normal cells and tumor cells through gene therapy, induces pyroptosis in tumor cells, and has no effect on normal cells.

[0021] b. It induces anti-tumor immune effects while killing tumor cells, with significant effects.

[0022] c. Activates anti-tumor immune surveillance effects, effectively preventing tumor recurrence.

[0023] d. It provides a platform for targeting and killing tumor cells, promoting the research and development of similar gene-based anti-cancer products. Attached Figure Description

[0024] Figure 1A , 1B Figures 1 and 1C represent plasmid diagrams and schematic diagrams carrying pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP, respectively.

[0025] Figure 1D The artificial promoters pETV4 and pSurvivin were activated in bladder cancer cell lines UM-UC-3 and T24, but not in the normal bladder epithelial cell line SV-HUC-1; the pTP53 bladder cancer cell lines UM-UC-3 and T24 were not activated, but were activated in the normal bladder epithelial cell line SV-HUC-1.

[0026] Figure 2A , 2B 2C, 2D: Plasmid diagrams of four plasmids carrying Gal4-int1, int2-VP64-NLS-FUS, int2-KRAB-NLS, and UAS-EGFP, respectively.

[0027] Figure 2EThe downstream effector protein EGFP is only activated and expressed when Gal4-int1 and int2-VP64-NLS-FUS are transiently transduced into cells simultaneously, while int2-KRAB-NLS is not transiently transduced into cells; and the addition of the phase-separation domain FUS can further enhance the activation effect.

[0028] Figure 2F The logic processing mode of a three-input logic gate system is AAND B NOT C.

[0029] Figure 3A NT-GSDMD showed the best pyroptosis-inducing effect compared to other NT-GSDM proteins.

[0030] Figure 3B , 3C 3D: Schematic diagrams and plasmid diagrams of plasmid 1 carrying pETV4-Gal4-int1, pSurvivin-int2-VP64-NLS-FUS and pTP53-int2-KRAB-NLS and plasmid 2 carrying UAS-NT-GSDMD.

[0031] Figure 3E The gene circuit can target and induce pyroptosis in tumor cell lines UM-UC-3, T24, MDA-MB-231 and A375, without inducing pyroptosis in the normal bladder epithelial cell line SV-HUC-1. Detailed Implementation

[0032] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0033] 1. This application provides an artificial promoter pETV4 that can sense the expression level of ETV4 in cells, and an artificial promoter combination that can distinguish between normal cells and tumor cells: pETV4, pSurvivin, and pTP53. Furthermore, by combining pETV4, pSurvivin, and pTP53 with EGFP at their 3' ends, we constructed artificial promoter assay systems pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP.

[0034] 1.1pETV4 consists of the 5' end sequence 12X ETV4 binding site and the 3' end sequence core promoter miniCMV.

[0035] 1.2 The sequence of the ETV4 binding site is accggaagt, and there are a total of 12 groups.

[0036] 1.3ETV4 binding sites are spaced 1-5 random bases apart.

[0037] 1.4 The sequence of miniCMV (SEQ ID NO:1) is:

[0038] GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC.

[0039] 1.5 There are 5 - 10 random base pairs between the 12X ETV4 binding site and the core promoter miniCMV. 1.6 The sequence of pETV4 (SEQ ID NO:2) is:

[0040] accggaagtgaccggaagtgaccggaagtgagaccggaagtgaccggaagtgaccggaagtgtg

[0041] gaccggaagtgaccggaagtgaccggaagtgccagacaccggaagtgaccggaagtgaccggaa

[0042] gtgtatataagggggtgggggcgttcgtcctcactctagatctgcgatctaagtaagcttggca

[0043] ttccggtactgttggtaaaccagctcgccaccgaattctgcagtcgacggtaccgcgggcccgggatccaccggtcgccacc.

[0044] 1.7 The sequence of pSurvivin (SEQ ID NO:3) is:

[0045] acgcgttctttgaaagcagtcgagggggcgctaggtgtgggcagggacgagctggcgcggcgtc

[0046] gctgggtgcaccgcgaccacgggcagagccacgcggcgggaggactacaactcccggcacaccc

[0047] cgcgccgccccgcctctactcccagaaggccgcggggggtggaccgcctaagagggcgtgcgct

[0048] cccgacatgccccgcggcgcgccattaaccgccagatttgaatcgcgggacccgttggcagaggtggcggcggcggc.

[0049] The sequence of 1.8pTP53 (SEQ ID NO:4) is as follows:

[0050] caggtgcctgtcgggtcactagtgtgaacgctgcgcgtagtctgggcgggattgggccggttca

[0051] gtgggcaggttgactcagcttttcctcttgagctggtcaagttcagacacgttccgaaactgca

[0052] gtaaaaggagttaagtcctgacttgtctccagctggggctatttaaaccatgcattttcccagctgtgttca.

[0053] 1.9 To test the ability of pETV4, pSurvivin, and pTP53 to distinguish between normal and tumor cells, we constructed artificial promoter assay systems pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP by combining pETV4, pSurvivin, and pTP53 with EGFP at their 3' ends, respectively.

[0054] The sequence of 1.10pETV4-EGFP (SEQ ID NO:5) is as follows:

[0055] accggaagtgaccggaagtgaccggaagtgagaccggaagtgaccggaagtgaccggaagtgtg

[0056] gaccggaagtgaccggaagtgaccggaagtgccagacaccggaagtgaccggaagtgaccggaa

[0057] gtgtatataagggggtgggggcgttcgtcctcactctagatctgcgatctaagtaagcttggca

[0058] ttccggtactgttggtaaaccagctcgccaccgaattctgcagtcgacggtaccgcgggcccgg

[0059] gatccaccggtcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcc

[0060] tggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcga

[0061] tgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctgg

[0062] cccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatga

[0063] agcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttctt

[0064] caaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaac

[0065] cgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaaggctggagt

[0066] acaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaa

[0067] cttcaagatccgccacaacaatcgaggacggcagcgtgcagctcgccgaccactaccagcagaac

[0068] acccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgcc

[0069] tgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagTGA。 The sequence of 1.11pSurvivin-EGFP (SEQ ID NO:6) is:

[0070] 1.11pSurvivin-EGFP's sequence (SEQ ID NO:6) is:

[0071] acgcgttctttgaaagcagtcgagggggcgctaggtgtgggcagggacgagctggcgcggcgtcg acgcgttctttgaaagcagtcgagggggcgctaggtgtgggcagggacgagctggcgcggcgtcg

[0072] ctgggtgcaccgcgaccacgggcagagccacgcggcgggaggactacaactcccggcacaccccg ctgggtgcaccgcgaccacgggcagagccacgcggcgggaggactacaactcccggcacaccccg

[0073] cgccgccccgcctctactcccagaaggccgcggggggtggaccgcctaagagggcgtgcgctccc cgccgccccgcctctactcccagaaggccgcggggggtggaccgcctaagagggcgtgcgctccc

[0074] gacatgccccgcggcgcgccattaaccgccagatttgaatcgcgggacccgttggcagaggtggc gacatgccccgcggcgcgccattaaccgccagatttgaatcgcgggacccgttggcagaggtggc

[0075] ggcggcggcTCTAGAGCTAGCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGT ggcggcggcTCTAGAGCTAGCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGT

[0076] GCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG GCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG <0OO0169>AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTG AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTG

[0078] CCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCA CCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCA

[0079] CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCT CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCT

[0080] TCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG

[0081] AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGA

[0082] GTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGA

[0083] ACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAAC

[0084] ACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCT

[0085] GAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTGA。

[0086] 1. The sequence of 1.12pTP53-EGFP (SEQ ID NO:7) is:

[0087] caggtgcctgtcgggtcactagtgtgaacgctgcgcgtagtctgggcgggattgggccggttca

[0088] gtgggcaggttgactcagcttttcctcttgagctggtcaagttcagacacgttccgaaactgca

[0089] gtaaaaggagttaagtcctgacttgtctccagctggggctatttaaaccatgcattttcccagc

[0090] tgtgttcaGGATCCCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGA

[0091] CCTCCATAGAAGATTCTAGAGCTAGCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGG

[0092] GGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGC

[0093] GAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGC

[0094] TGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTA

[0095] CCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAG

[0096] CGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG

[0097] ACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGG

[0098] GCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC

[0099] GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC

[0100] ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAG

[0101] CACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTGA.

[0102] 1.13 pETV4 and pSurvivin can be simultaneously activated in tumor cell lines but not in normal cell lines; pTP53 is activated in normal cell lines but not in tumor cell lines. Tumor cell lines include, but are not limited to, UM-UC-3 and T24; normal cell lines include, but are not limited to, SV-HUC-1.

[0103] 2. This application provides a three-input logic gate system composed of the fusion proteins Gal4-int1, int2-VP64-NLS-FUS, and int2-KRAB-NLS. Gal4-int1 is connected to pETV4 at its 5' end, int2-VP64-NLS-FUS is connected to pSurvivin at its 5' end, and int2-KRAB-NLS is connected to pTP53 at its 5' end. This system can integrate, amplify, and process signals transmitted by artificial promoters in an A AND B NOTC logic format, thereby achieving efficient differentiation between normal cells and tumor cells.

[0104] 2.1 Gal4-int1 consists of Gal4, linker1 and int1 from the 5' end to the 3' end.

[0105] 2.2 The sequence of Gal4 (SEQ ID NO:8) is as follows:

[0106] atgaagctgctgagcagcatcgagcaggcctgtgacatctgccggctgaagaaactgaagtgcagcaa

[0107] agaaaagcccaagtgcgccaagtgcctgaagaacaactggggagtgccggtacagccccaagaccaaga

[0108] gaagccccctgaccagagcccacctgaccgaggtggaaagccggctggaaagactggaacagctgttt

[0109] ctgctgatcttcccacgcgaggacctggacatgatcctgaagatggacagcctgcaggacatcaaggc

[0110] cctgctgaccggcctgttcgtgcaggacaacgtgaacaaggacgccgtgaccgacagactggccagcg

[0111] tggaaaccgacatgcccctgaccctgcggcagcacagaatcagcgccaccagcagcagcgaggaaagcagcaacaagggccagcggcagctgacagtgtct。

[0112] 2.3. The linker1 sequence (SEQ ID NO:9) is:

[0113] gctgctgcaggcggaagcggaggctctggcggatct。

[0114] 2.4. The int1 sequence (SEQ ID NO:10) is

[0115] TGTCTGTCATACGAAACTGAGATACTGACGGTGGAATATGGTCTCCTTCCTATTGGGAAAATAGTGGA

[0116] AAAGAGGATCGAGTGTACGGTTTACTCAGTGGACAACAATGGGAATATCTATACGCAACCTGTCGCTC

[0117] AGTGGCATGATCGAGGGGAACAGGAGGTGTTTGAGTACTGTTTGGAGGACGGTTCTCTTATTCGGGCT

[0118] ACTAAGGACCACAAGTTTATGACAGTTGATGGTCAGATGTTGCCCATCGACGAGATATTTGAGCGGGAACTCGATTTGATGCGGGTTGATAATCTGCCGAAT。

[0119] 2.5. Gal4-int1 is linked to pETV4 at its 5' end through linker2. The linker2 sequence (SEQ ID NO:11) is: GTATACGCCACC

[0120] 2.6. The sequence of pETV4-Gal4-int1 (SEQ ID NO:12) is:

[0121] accggaagtgaccggaagtgaccggaagtgagaccggaagtgaccggaagtgaccggaagtgtggacc

[0122] ggaagtgaccggaagtgaccggaagtgccagacaccggaagtgaccggaagtgaccggaagtgtatat

[0123] aagggggtgggggcgttcgtcctcactctagatctgcgatctaagtaagcttggcattccggtactgt

[0124] tggtaaaccagctcgccaccgaattctgcagtcgacggtaccgcgggcccgggatccaccggtcgcca

[0125] ccGTATACGCCACCatgaagctgctgagcagcatcgagcaggcctgtgacatctgccggctgaagaaa

[0126] ctgaagtgcagcaaagaaaagcccaagtgcgccaagtgcctgaagaacaactgggagtgccggtacag

[0127] ccccaagaccaagagaagccccctgaccagagcccacctgaccgaggtggaaagccggctggaaagac

[0128] tggaacagctgtttctgctgatcttcccacgcgaggacctggacatgatcctgaagatggacagcctg

[0129] caggacatcaaggccctgctgaccggcctgttcgtgcaggacaacgtgaacaaggacgccgtgaccga

[0130] cagactggccagcgtggaaaccgacatgcccctgaccctgcggcagcacagaatcagcgccaccagca

[0131] gcagcgaggaaagcagcaacaagggccagcggcagctgacagtgtctgctgctgcaggcggaagcgga

[0132] ggctctggcggatctTGTCTGTCATACGAAACTGAGATACTGACGGTGGAATATGGTCTCCTTCCTAT

[0133] TGGGAAAATAGTGGAAAAGAGGATCGAGTGTACGGTTTACTCAGTGGACAACAATGGGAATATCTATA

[0134] CGCAACCTGTCGCTCAGTGGCATGATCGAGGGGAACAGGAGGTGTTTGAGTACTGTTTGGAGGACGGT

[0135] TCTCTTATTCGGGCTACTAAGGACCACAAGTTTATGACAGTTGATGGTCAGATGTTGCCCATCGACGAGATATTTGAGCGGGAACTCGATTTGATGCGGGTTGATAATCTGCCGAATTGA。

[0136] 2.7. pETV4-Gal4-int1 is linked to the transcription termination signal sequence hGH poly(A)signal at its 3' end, separated by several bases. The hGH poly(A)signal sequence (SEQ ID NO:13) is: GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAAT CTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCCAGCTAATTTTTGTTTTTTTGGTAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGCCTCCCCAAATTGCTGGGATTACAGGGCTGAACCACTGCTCCTTCCCTGTCCTT.

[0137] 2.8 The int2-VP64-NLS-FUS consists of the following parts, from the 5' end to the 3' end: int2, linker3, VP64, linker4, NLS, linker5 and FUS.

[0138] 2.9 The sequence of int2 (SEQ ID NO:14) is:

[0139] atgaagctgctgagcagcatcgagcaggcctgtgacatctgccggctgaagaaactgaagtgcagcaa

[0140] agaaaagcccaagtgcgccaagtgcctgaagaacaactggggagtgccggtacagccccaagaccaaga

[0141] gaagccccctgaccagagcccacctgaccgaggtggaaagccggctggaaagactggaacagctgttt

[0142] ctgctgatcttcccacgcgaggacctggacatgatcctgaagatggacagcctgcaggacatcaaggc

[0143] cctgctgaccggcctgttcgtgcaggacaacgtgaacaaggacgccgtgaccgacagactggccagcg

[0144] tggaaaccgacatgcccctgaccctgcggcagcacagaatcagcgccaccagcagcagcgaggaaagcagcaacaagggccagcggcagctgacagtgtct。

[0145] 2.10. The linker3 sequence (SEQ ID NO:15) is: GGAGGTTCTGGCAGCGGTTCCGGTGGCTCA.

[0146] 2.11. The VP64 sequence (SEQ ID NO:16) is:

[0147] gatgccctggacgacttcgacctggatatgctgggcagcgacgccctggatgattttgatctggacat

[0148] gctgggatctgacgctctggacgatttcgatctcgacatgttgggatcagatgcactggatgactttgacctggacatgctc.

[0149] 2.12. The linker4 sequence (SEQ ID NO:17) is: GGAGGAGGCTCCGGGGAAGAT.

[0150] 2.13. The NLS sequence (SEQ ID NO:18) is: CCTAAGAAGAAGCGGAAAGTG.

[0151] 2.14. The linker5 sequence is: GGATCC.

[0152] 2.15. The FUS sequence (SEQ ID NO:19) is:

[0153] ATGGCCTCAAACGATTATACCCAACAAGCAACCCAAAGCTATGGGGCCTACCCCACCCAGCCCGGGCA

[0154] GGGCTATTCCCAGCAGAGCAGTCAGCCCTACGGACAGCAGAGTTACAGTGGTTATAGCCAGTCCACGG

[0155] ACACTTCAGGCTATGGCCAGAGCAGCTATTCTTCTTATGGCCAGAGCCAGAACACAGGCTATGGAACT

[0156] CAGTCAACTCCCCAGGGATATGGCTCGACTGGCGGCTATGGCAGTAGCCAGAGCTCCCAATCGTCTTA

[0157] CGGGCAGCAGTCCTCCTACCCTGGCTATGGCCAGCAGCCAGCTCCCAGCAGCACCTCGGGAAGTTACG

[0158] GTAGCAGTTCTCAGAGCAGCAGCTATGGGCAGCCCCAGAGTGGGAGCTACAGCCAGCAGCCTAGCTAT

[0159] GGTGGACAGCAGCAAAGCTATGGACAGCAGCAAAGCTATAATCCCCCTCAGGGCTATGGACAGCAGAA

[0160] CCAGTACAACAGCAGCAGTGGTGGTGGAGGTGGAGGTGGAGGTGGAGGTAACTATGGCCAAGATCAAT

[0161] CCTCCATGAGTAGTGGTGGTGGCAGTGGTGGCGGTTATGGCAATCAAGACCAGAGTGGTGGAGGTGGCAGCGGTGGCTATGGACAGCAGGACCGTGGATGA。

[0162] 2.16. int2-VP64-NLS-FUS is linked to pSurvivin at the 5'-end via linker8, and the linker8 sequence (SEQ ID NO: 20) is: GCGGCCGCCGCCACC.

[0163]

[0164] 2.18. pSurvivin-int2-VP64-NLS-FUS is linked to the transcription termination signal sequence Tm.synth.20 at the 3' end by several bases. The sequence of Tm.synth.20 (SEQ ID NO:22) is: CACACAAAAAACCAACACACAGAAAAACACATTaaagcttaaaattcaTTTATTTTACATTACATTAC ATTACA.

[0165] 2.19. The int2-KRAB-NLS consists of the following parts, from the 5' end to the 3' end: int2, linker3, KRAB, linker4, NLS.

[0166] 2.20. The sequence of int2 is the same as the int2 sequence in 2.9 above.

[0167] 2.21 The sequence of linker3 is the same as the linker3 sequence in 2.10 above.

[0168] 2.22. The sequence of KRAB (SEQ ID NO:23) is as follows:

[0169] AGAACACTGGTTACGTTCAAGGACGTGTTTGTGGACTTTACACGTGAGGAGTGGAAATTGCTGGATAC

[0170] TGCGCAACAAATTGTGTATCGAAATGTCATGCTTGAGAATTACAAGAACCTCGTCAGTCTCGGATACCAGTTGACGAAACCGGATGTGATCCTTAGGCTCGAAAAGGGGGAAGAACCTTGGCTGGTA.

[0171] 2.23. The sequence of linker4 is the same as the linker4 sequence in 2.12 above.

[0172] 2.24. The NLS sequence is the same as the NLS sequence in 2.13 above.

[0173] 2.25. The int2-KRAB-NLS is connected to pTP53 at its 5' end via linker 6. The linker 6 sequence (SEQ ID NO:24) is: TTAATTAAACGCCACC.

[0174] 2.26. The sequence of pTP53-int2-KRAB-NLS (SEQ ID NO:25) is: caggtgcctgtcgggtcactagtgtgaacgctgcgcgtagtctgggcgggattgggccggttcagtgggcaggttgactcagcttttcctcttgagctggtcaagttcagacacgttccgaaactgcagtaaaaggagttaagtcctgacttgtctccagctggggctatttaaaccatgcattttcccagctgtgttcaTTAATTAACGCCACCATGATAAAGATCGCCACTCGGAAGTATTTGGGGAAACAGAACGTGTATGATATTGGTGTCGAGAGAGACCACAACTTTGCACTTAAGAATGGGTTCATAGCGTCTGGAGGTTCTGGCAGCGGTTCCGGTGGCTCAAGAACACTGGTTACGTTCAAGGACGTGTTTGTGGACTTTACACGTGAGGAGTGGAAATTGCTGGATACTGCGCAACAAATTGTGTATCGAAATGTCATGCTTGAGAATTACAAGAACCTCGTCAGTCTCGGATACCAGTTGACGAAACCGGATGTGATCCTTAGGCTCGAAAAGGGGGAAGAACCTTGGCTGGTAGGAGGAGGCTCCGGGGAAGATCCTAAGAAGAAGCGGAAAGTGTAG。

[0175] 2.27. pTP53-int2-KRAB-NLS is linked to the transcription termination signal sequence Rabbit globin poly A by several bases at its 3' end. The Rabbit globin poly A sequence (SEQ ID NO:26) is

[0176] gatctttttccctctgccaaaaattatggggacatcatgaagccccttgagcatctgacttctggctaataaaggaaatttattttcattgcaatagtgtgttggaattttttgtgtctctcactcg。

[0177] 2.28 The above-mentioned pETV4-Gal4-int1, pSurvivin-int2-VP64-NLS-FUS, pTP53-int2-KRAB-NLS and UAS-NT-GSDM modules can be integrated into the same plasmid vector or multiple plasmid vectors; the modules can be spaced 1-100 bp apart with random sequences from different sources.

[0178] 2.29. The test effector UAS-EGFP consists of a UAS promoter and an EGFP, separated by 1-10 base pairs.

[0179] 2.30. The UAS promoter sequence (SEQ ID NO:27) is as follows:

[0180] TAGACGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCGACTCGAGCGGAGTACTGTCCTCCGATCG

[0181] GAGTACTGTCCTCCGCGAATTCCGGAGTACTGTCCTCCGAAGACGCTAGCGGGGGGCTATAAAAGGGGGTGGGGGCGTTCGTCCTCACTCT.

[0182] 2.31. The EGFP sequence (SEQ ID NO:28) is as follows:

[0183] ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTGA。

[0184] 2.32. The sequence of UAS-EGFP (SEQ ID NO:29) is as follows:

[0185] TAGACGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCGACTCGAGCGGAGTACTGTCCTCCGATCG

[0186] GAGTACTGTCCTCCGCGAATTCCGGAGTACTGTCCTCCGAAGACGCTAGCGGGGGGCTATAAAAGGGG

[0187] GTGGGGGCGTTCGTCCTCACTCTaagcttggatccGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTC

[0188] ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGG

[0189] CGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGC

[0190] CCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGAC

[0191] CACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT

[0192] CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACC

[0193] GCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC

[0194] TACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGAT

[0195] CCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCG

[0196] ACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAAC

[0197] GAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTGA.

[0198] 2.33. UAS-EGFP is linked to the transcription termination signal sequence bGH poly(A)signal at the 3' end, separated by several bases. The bGH poly(A)signal sequence (SEQ ID NO:30) is: ctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatgg.

[0199] 3. This application provides a method for specifically delivering NT-GSDM into tumor cells via artificial gene circuitry: constructing a UAS-NT-GSDM effector, which is activated when the output of the above three-input logic gate system is positive, thereby targeting and inducing pyroptosis of tumor cells, while promoting the occurrence of anti-tumor immune responses and effectively enhancing the effect of tumor treatment.

[0200] 3.1 The UAS-NT-GSDM consists of a 5' end sequence UAS promoter and a 3' end sequence NT-GSDM, which are connected by linker7.

[0201] 3.2 The UAS promoter sequence is the same as in 2.30.

[0202] 3.3 The sequence of linker7 (SEQ ID NO:31) is: aagcttggatccGCCACC.

[0203] 3.4 NT-GSDM can be the N-terminal sequence of GSDMA, GSDMB1, GSDMB2, GSDMB3, GSDMB4, GSDMB5, GSDMC, GSDMD, or GSDME proteins.

[0204] N-terminal sequence of GSDMA (NT-GSDMA) (SEQ ID NO:32):

[0205] atgaccatgtttgaaaatgtcacccgggccctggccagacagctaaaccctcgaggggacctgacacc

[0206] acttgacagcctcatcgacttcaagcgcttccatcccttctgcctggtgctgaggaagaggaagagca

[0207] cgctcttctggggggcccggtacgtccgcaccgactacacgctgctggatgtgcttgagcccggcagc

[0208] tcaccttcagacccaacagacactgggaattttggctttaagaatatgctggacacccgagtggaggg

[0209] agatgtggatgtaccaaagacggtgaaggtgaagggaacggcagggctctcgcagaacagcactctgg

[0210] aggtccagacactcagtgtggctcccaaggccctggagaccgtgcaggagaggaagctggcagcagac

[0211] cacccattcctgaaggagatgcaagatcaaggggagaacctgtatgtggtgatggaggtggtggagac

[0212] ggtgcaggaggtcacactggagcgagccggcaaggcagaggcctgcttctccctccccttcttcgccc

[0213] cattggggctacagggatccataaatcacaaggaggctgtaaccatccccaagggctgcgtcctggcc

[0214] tttcgagtgagacagctgatggtcaaaggcaaagatgagtgggatattccacatatctgcaatgataacatgcaaaccttccctcctggagaaaagtcaggagaggagaaggtcatccttatccagTAA。

[0215] The N-terminal sequence of GSDMB1 (NT-GSDMB1) (SEQ ID NO: 33):

[0216] ATGTTCAGCGTATTTGAGGAAATCACAAGAATTGTAGTTAAGGAGATGGATGCTGGAGGGGATATGAT

[0217] TGCCGTTAGAAGCCTTGTTGATGCTGATAGATTCCGCTGCTTCCATCTGGTGGGGGAGAAGAGAACTT

[0218] TCTTTGGATGCCGGCACTACACAACAGGCCTCACCCTGATGGACATTCTGGACACAGATGGGGACAAG

[0219] TGGTTAGATGAACTGGATTCTGGGCTCCAAGGTCAAAAGGCTGAGTTTCAAATTCTGGATAATGTAGA

[0220] CTCAACGGGAGAGTTGATAGTGAGATTACCCAAAGAAATAACAATTTCAGGCAGTTTCCAGGGCTTCC<s

[0221] ACCATCAGAAAATCAAGATATCGGAGAACCGGATATCCCAGCAGTATCTGGCTACCCTTGAAAACAGG

[0222] AAGCTGAAGAGGGAACTACCCTTTTCATTCCGATCAATTAATACGAGAGAAAACCTGTATCTGGTGAC

[0223] AGAAACTCTGGAGACGGTAAAGGAGGAAACCCTGAAAAGCGACCGGCAATATAAATTTTGGAGCCAGA

[0224] TCTCTCAGGGCCATCTCAGCTATAAACACAAGGGCCAAAGGGAAGTGACCATCCCCCCAAATCGGGTC

[0225] CTGAGCTATCGAGTAAAGCAGCTTGTCTTCCCCAACAAGGAGACGATGAAAAAGGATGGTGCTTCATCCTGTTTATAA。

[0226] The N-terminal sequence of GSDMB2 (NT-GSDMB2) (SEQ ID NO:34):

[0227] ATGTTCAGCGTATTTGAGGAAATCACAAGAATTGTAGTTAAGGAGATGGATGCTGGAGGGGATATGAT

[0228] TGCCGTTAGAAGCCTTGTTGATGCTGATAGATTCCGCTGCTTCCATCTGGTGGGGGAGAAGAGAACTT

[0229] TCTTTGGATGCCGGCACTACACAACAGGCCTCACCCTGATGGACATTCTGGACACAGATGGGGACAAG

[0230] TGGTTAGATGAACTGGATTCTGGGCTCCAAGGTCAAAAGGCTGAGTTTCAAATTCTGGATAATGTAGA

[0231] CTCAACGGGAGAGTTGATAGTGAGATTACCCAAAGAAATAACAATTTCAGGCAGTTTCCAGGGCTTCC

[0232] ACCATCAGAAAATCAAGATATCGGAGAACCGGATATCCCAGCAGTATCTGGCTACCCTTGAAAACAGG

[0233] AAGCTGAAGAGGGAACTACCCTTTTCATTCCGATCAATTAATACGAGAGAAAACCTGTATCTGGTGAC

[0234] AGAAACTCTGGAGACGGTAAAGGAGGAAACCCTGAAAAGCGACCGGCAATATAAATTTTGGAGCCAGA

[0235] TCTCTCAGGGCCATCTCAGCTATAAACACAAGGGCCAAAGGGAAGTGACCATCCCCCCAAATCGGGTCCTGAGCTATCGAGTAAAGCAGCTTGTCTTCCCCAACAAGGAGACGATGTAA。

[0236] The N-terminal sequence of GSDMB3 (NT-GSDMB3) (SEQ ID NO: 35):

[0237] ATGTTCAGCGTATTTGAGGAAATCACAAGAATTGTAGTTAAGGAGATGGATGCTGGAGGGGATATGAT

[0238] TGCCGTTAGAAGCCTTGTTGATGCTGATAGATTCCGCTGCTTCCATCTGGTGGGGGAGAAGAGAACTT

[0239] TCTTTGGATGCCGGCACTACACAACAGGCCTCACCCTGATGGACATTCTGGACACAGATGGGGACAAG

[0240] TGGTTAGATGAACTGGATTCTGGGCTCCAAGGTCAAAAGGCTGAGTTTCAAATTCTGGATAATGTAGA

[0241] CTCAACGGGAGAGTTGATAGTGAGATTACCCAAAGAAATAACAATTTCAGGCAGTTTCCAGGGCTTCC

[0242] ACCATCAGAAAATCAAGATATCGGAGAACCGGATATCCCAGCAGTATCTGGCTACCCTTGAAAACAGG

[0243] AAGCTGAAGAGGGAACTACCCTTTTCATTCCGATCAATTAATACGAGAGAAAACCTGTATCTGGTGAC

[0244] AGAAACTCTGGAGACGGTAAAGGAGGAAACCCTGAAAAGCGACCGGCAATATAAATTTTGGAGCCAGA

[0245] TCTCTCAGGGCCATCTCAGCTATAAACACAAGGGCCAAAGGGAAGTGACCATCCCCCCAAATCGGGTC

[0246] CTGAGCTATCGAGTAAAGCAGCTTGTCTTCCCCAACAAGGAGACGATGAATATTCATTTCAGGGGCAAAACAAAATCCTTTCCAGAAGAGAAGGATGGTGCTTCATCCTGTTTAGGAAAGTCTTTGTGA。

[0247] N-terminal sequence of GSDMB4 (NT-GSDMB4) (SEQ ID NO:36):

[0248] ATGTTCAGCGTATTTGAGGAAATCACAAGAATTGTAGTTAAGGAGATGGATGCTGGAGGGGATATGAT

[0249] TGCCGTTAGAAGCCTTGTTGATGCTGATAGATTCCGCTGCTTCCATCTGGTGGGGGAGAAGAGAACTT

[0250] TCTTTGGATGCCGGCACTACACAACAGGCCTCACCCTGATGGACATTCTGGACACAGATGGGGACAAG

[0251] TGGTTAGATGAACTGGATTCTGGGCTCCAAGGTCAAAAGGCTGAGTTTCAAATTCTGGATAATGTAGA

[0252] CTCAACGGGAGAGTTGATAGTGAGATTACCCAAAGAAATAACAATTTCAGGCAGTTTCCAGGGCTTCC

[0253] ACCATCAGAAAATCAAGATATCGGAGAACCGGATATCCCAGCAGTATCTGGCTACCCTTGAAAACAGG

[0254] AAGCTGAAGAGGGAACTACCCTTTTCATTCCGATCAATTAATACGAGAGAAAACCTGTATCTGGTGAC

[0255] AGAAACTCTGGAGACGGTAAAGGAGGAAACCCTGAAAAGCGACCGGCAATATAAATTTTGGAGCCAGA

[0256] TCTCTCAGGGCCATCTCAGCTATAAACACAAGGGCCAAAGGGAAGTGACCATCCCCCCAAATCGGGTC

[0257] CTGAGCTATCGAGTAAAGCAGCTTGTCTTCCCCAACAAGGAGACGATGAATATTCATTTCAGGGGCAAAACAAAATCCTTTCCAGAATAA。

[0258] The N-terminal sequence of GSDMB5 (NT-GSDMB5) (SEQ ID NO:37):

[0259] ATGTTCAGCGTATTTGAGGAAATCACAAGAATTGTAGTTAAGGAGATGGATGCTGGAGGGGATATGAT

[0260] TGCCGTTAGAAGCCTTGTTGATGCTGATAGATTCCGCTGCTTCCATCTGGTGGGGGAGAAGAGAACTT

[0261] TCTTTGGATGCCGGCACTACACAACAGGCCTCACCCTGATGGACATTCTGGACACAGATGGGGACAAG<MISSING END TAG FOR <MISSING END TAG FOR

[0262] TGGTTAGATGAACTGGATTCTGGGCTCCAAGGTCAAAAGGCTGAGTTTCAAATTCTGGATAATGTAGA

[0263] CTCAACGGGAGAGTTGATAGTGAGATTACCCAAAGAAATAACAATTTCAGGCAGTTTCCAGGGCTTCC

[0264] ACCATCAGAAAATCAAGATATCGGAGAACCGGATATCCCAGCAGTATCTGGCTACCCTTGAAAACAGG

[0265] AAGCTGAAGAGGGAACTACCCTTTTCATTCCGATCAATTAATACGAGAGAAAACCTGTATCTGGTGAC

[0266] It seems there are some missing end tags in the original text which might cause issues in a proper XML or structured context. The translation is done as accurately as possible based on the provided text.AGAAACTCTGGAGACGGTAAAGGAGGAAACCCTGAAAAGCGACCGGCAATATAAATTTTGGAGCCAGATCTCTCAGGGCCATCTCAGCTATAAACACAAGTAA。

[0267] The N-terminal sequence of GSDMC (NT-GSDMC) (SEQ ID NO:38):

[0268] atgccctccatgttggaacgcattagcaaaaatttggtcaaagagattggaagcaaagacctgacacc

[0269] tgtcaaatacctattgagtgccaccaaattacgtcagtttgttatattacgaaagaagaaggattctc

[0270] gttcatcattttgggaacaatctgactatgttccagttgaattctccctcaatgacatcctggagcca

[0271] agttcttcagtcctagaaactgttgtgacaggaccgttccacttcagtgacattatgatccagaagca

[0272] taaggctgacatgggtgtgaatgttggtatagaagtgagtgtgtcaggggaggcctctgtggaccatg

[0273] gatgctccctcgagtttcaaattgttaccatcccatcaccaaacctggaagactttcaaaaaaggaaa

[0274] ctgttggatccagagccatcatttctgaaggagtgccggaggagaggggacaacctgtacgtggtgac

[0275] agaggctgttgaactgatcaacaatactgtgctgtacgatagcagtagtgtgaatattttagggaaaa

[0276] ttgctctttggattacctatggcaagggtcaaggccaaggagagagtctcagagtgaagaagaaggcg

[0277] ctgactcttcagaaaggcatggtgatggcttataagagaaagcagctggttatcaaggagaaagccattctcatctcagatgatgatgaacagagaacctttcaagatTAA。

[0278] The N-terminal sequence of GSDMD (NT-GSDMD) (SEQ ID NO: 39) is:

[0279] atggggtcggcctttgagcgggtagtccggagagtggtccaggagctggaccatggtggggagttcat

[0280] ccctgtgaccagcctgcagagctccactggcttccagccctactgcctggtggttaggaagccctcaa

[0281] gctcatggttctggaaaccccgttataagtgtgtcaacctgtctatcaaggacatcctggagccggat

[0282] gccgcggaaccagacgtgcagcgtggcaggagcttccacttctacgatgccatggatgggcagataca

[0283] [[ID=二十一]]gggcagcgtggagctggcagccccaggacaggcaaagatcgcaggcggggccgcggtgtctgacagct

[0284] ccagcacctcaatgaatgtgtactcgctgagtgtggaccctaacacctggcagactctgctccatgag

[0285] aggcacctgcggcagccagaacacaaagtcctgcagcagctgcgcagccgcggggacaacgtgtacgt

[0286] ggtgactgaggtgctgcagacacagaaggaggtggaagtcacgcgcacccacaagcgggagggctcgg

[0287] gccggttttccctgcccggagccacgtgcttgcagggtgagggccagggccatctgagccagaagaag

[0288] acggtcaccatcccctcaggcagcaccctcgcattccgggtggcccagctggttattgactctgactt

[0289] ggacgtccttctcttcccggataagaagcagaggaccttccagccacccgcgacaggccacaagcgtt

[0290] ccacgagcgaaggcgcctggccacagctgccctctggcctctccatgatgaggtgcctccacaacttcctgacagatTGA。

[0291] N-terminal sequence of GSDME (NT-GSDME) (SEQ ID NO:40):

[0292] atgtttgccaaagcaaccaggaattttcttagagaagttgatgctgatggtgacctgattgcagtatc

[0293] aaatctgaatgactctgataagttacagcttctaagtctggtgacaaaaaagaagagattctggtgct

[0294] ggcagagacccaagtaccagtttttatccctcacccttggcgatgtactcatagaagaccaatttccg

[0295] agtccagtggtcgtggagtcggactttgtgaaatacgagggcaagtttgcaaaccacgtgagtggaac

[0296] cctggagactgcactggggaaggtcaagctgaacctggggggcagcagccgcgtagagagccagtctt

[0297] catttggaaccctgaggaagcaggaggtggatttgcagcagctcatcagagactctgccgagagaaca

[0298] ataaatctgagaaaccctgtgctccagcaggtgctggaaggaaggaatgaggtcctgtgcgttttgac

[0299] acagaagatcacgacgatgcagaagtgtgtgatctctgagcacatgcaggtcgaggagaagtgtggtg

[0300] gcatcgtgggcatccagaccaagacggtgcaggtgtcagcgacggaggatgggaatgtcaccaaggac

[0301] tccaacgtggtgctggagatcccagctgccaccaccattgcctacggtgtcattgagttatacgtgaa

[0302] actggacggccagttcgagttctgccttctccgagggaagcaaggtggcttcgagaacaagaagagaattgactctgtctacctggaccccctggtctttcgagagtttgcattcatagacatgccagatTGA.

[0303] 3.5. Preferably, NT-GSDMD induces the best pyrolysis effect; specific experimental results are shown in Example 3. Figure 3A It was selected as an effector protein that induces pyroptosis in tumor cells.

[0304] 3.6 The sequence of UAS-NT-GSDMD (SEQ ID NO:41) is as follows:

[0305] TAGACGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCGACTCGAGCGGAGTACTGTCCTCCGATCG

[0306] GAGTACTGTCCTCCGCGAATTCCGGAGTACTGTCCTCCGAAGACGCTAGCGGGGGGCTATAAAAGGGG

[0307] GTGGGGGCGTTCGTCCTCACTCTaagcttggatccGCCACCatggggtcggcctttgagcgggtagtc

[0308] cggagagtggtccaggagctggaccatggtggggagttcatccctgtgaccagcctgcagagctccac

[0309] tggcttccagccctactgcctggtggttaggaagccctcaagctcatggttctggaaaccccgttata

[0310] agtgtgtcaacctgtctatcaaggacatcctggagccggatgccgcggaaccagacgtgcagcgtggc

[0311] aggagcttccacttctacgatgccatggatgggcagatacagggcagcgtggagctggcagccccagg

[0312] acaggcaaagatcgcaggcggggccgcggtgtctgacagctccagcacctcaatgaatgtgtactcgc

[0313] tgagtgtggaccctaacacctggcagactctgctccatgagaggcacctgcggcagccagaacacaaa

[0314] gtcctgcagcagctgcgcagccgcggggacaacgtgtacgtggtgactgaggtgctgcagacacagaa

[0315] ggaggtggaagtcacgcgcacccacaagcgggagggctcgggccggttttccctgcccggagccacgt

[0316] gcttgcagggtgagggccagggccatctgagccagaagaagacggtcaccatcccctcaggcagcacc

[0317] ctcgcattccgggtggcccagctggttattgactctgacttggacgtccttctcttcccggataagaa

[0318] gcagaggaccttccagccacccgcgacaggccacaagcgttccacgagcgaaggcgcctggccacagctgccctctggcctctccatgatgaggtgcctccacaacttcctgacagatTGA.

[0319] 4. This application provides an RNA delivery system, which includes any of the gene circuits described above and a delivery vector capable of delivering the gene circuits to the host's organ tissues for enrichment.

[0320] 4.1 The delivery vector for this gene pathway can be a viral vector or a non-viral vector. Viral vectors include adeno-associated virus vectors, adenovirus vectors, lentiviral vectors, and retroviral vectors. Non-viral vectors include plasmid vectors, liposome vectors, cationic polymer vectors, nanoparticle vectors, and multifunctional envelope-type nanocarriers.

[0321] 4.2 Preferably, the delivery vector is an adeno-associated virus vector or a plasmid vector. Specifically, the adeno-associated virus vector is preferably adeno-associated virus vector type 2 (AAV2).

[0322] 4.3 The drug can be administered orally, by inhalation, subcutaneously, intramuscularly, or intravenously. That is, the drug can enter the body via any of the above methods and then be delivered to the target tissue via the aforementioned gene pathway to exert its therapeutic effect.

[0323] 4.4 The dosage form of the drug may be tablets, capsules, powders, granules, pills, suppositories, ointments, solutions, suspensions, lotions, gels, or pastes, etc.

[0324] The proposed artificial promoter can sense the expression levels of transcription factors associated with tumor progression in cells. Specifically, pETV4 senses the expression level of the oncogenic transcription factor ETV4; pSurvivin senses the expression level of the oncogenic transcription factor Survivin; and pTP53 senses the expression level of the tumor suppressor transcription factor TP53. We obtained pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP assay systems by tandemly linking pETV4, pSurvivin, and pTP53 with the fluorescent protein EGFP. These systems were transfected into the normal bladder epithelial cell line SV-HUC-1 and bladder cancer cell lines UM-UC-3 and T24, respectively. The results showed that pETV4-EGFP and pSurvivin-EGFP were non-fluorescent in SV-HUC-1 but fluorescent in UM-UC-3 and T24; pTP53-EGFP showed strong fluorescence expression in SV-HUC-1 but weak fluorescence expression in UM-UC-3 and T24. In summary, the artificial promoter combination of pETV4, pSurvivin, and pTP53 can effectively distinguish between normal epithelial cell lines and bladder cancer cell lines.

[0325] Furthermore, we constructed a three-input logic gate system consisting of Gal4-int1, int2-VP64-NLS-FUS, and int2-KRAB-NLS, and used UAS-NT-GSDM as the tumor pyroptosis induction effector. Specifically, Gal4-int1 is connected to pETV4 at its 5' end, int2-VP64-NLS-FUS is connected to pSurvivin at its 5' end, and int2-KRAB-NLS is connected to pTP53 at its 5' end, ultimately yielding pETV4-Gal4-int1, pSurvivin-int2-VP64-NLS-FUS, and pTP53-int2-KRAB-NLS. In tumor cells, the artificial promoters pETV4 and pSurvivin are activated, while pTP53 is weakly activated or not activated. Therefore, Gal4-int1 and int2-VP64-NLS-FUS are highly expressed, while int2-KRAB-NLS is lowly expressed or not expressed. The int1 and int2 sequences mediate the covalent binding of their respective fusion proteins, which then detach from the system via self-cleavage, ultimately forming the novel fusion protein Gal4-VP64-NLS-FUS. Gal4 specifically binds to UAS, while FUS increases the local concentration of Gal4-VP64-NLS-FUS at the UAS promoter through a phase-separation effect. The transcriptional activation domain VP64 activates the expression of the downstream effector protein NT-GSMD, ultimately inducing pyroptosis in tumor cells. In normal cells, the artificial promoter pTP53 is activated, while pETV4 and pSurvivin are weakly or not activated. Therefore, int2-KRAB-NLS is highly expressed, while Gal4-int1 and int2-VP64-NLS-FUS are lowly or not expressed; ultimately, the novel fusion protein Gal4-KRAB-NLS-FUS is formed in the cell. The transcriptional repression domain KRAB inhibits NT-GSMD expression and does not induce pyroptosis in normal cells. In summary, this system can integrate, amplify, and process signals transmitted by artificial promoters in an A AND BNOT C logical form, thereby achieving efficient differentiation between normal cells and tumor cells.

[0326] The gene circuit (gene product) in this application can be delivered to tissues and organs such as the bladder via various viral or non-viral vectors. Subsequently, by sensing the expression of ETV4, Survivin and TP53 in cells, it can distinguish whether the cells are normal cells or tumor cells. Finally, it specifically expresses NT-GSDM protein in tumor cells, inducing pyroptosis and anti-tumor immune effects, thereby achieving targeted killing of tumors.

[0327] Example 1: The artificial promoter combination pETV4, pSurvivin and pTP53 can distinguish between normal cells and tumor cells.

[0328] In this embodiment, pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP assays were stably transfected into bladder cancer cell lines UM-UC-3 and T24, and normal bladder epithelial cell line SV-HUC-1, respectively, using lentiviruses. The expression of EGFP in the stably transfected cell lines was observed using an inverted fluorescence microscope to verify the activation effects of pETV4, pSurvivin, and pTP53 in tumor cell lines and normal epithelial cell lines.

[0329] Experimental methods:

[0330] 1. Bladder cancer cell lines UM-UC-3 and T24, normal bladder epithelial cell line SV-HUC-1, and human embryonic kidney cell line 293T were all purchased from the American Type Culture Collection (ATCC). UM-UC-3 was cultured in DMEM medium, T24 in RPMI-1640 medium, and SV-HUC-1 in Ham's F-12K medium. All media contained 10% fetal bovine serum, 50 U / ml penicillin, and 50 μg / ml streptomycin.

[0331] 2. The plasmid backbone is the pCDH plasmid, carrying an mCherry-labeled fluorescent protein and an ampicillin resistance gene, sourced from Guangzhou Aiji Biotechnology Co., Ltd. The pCDH plasmid was linearized by digestion with restriction endonucleases EcoRI and NotI. DNA fragments containing the sequences pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP were synthesized de novo, respectively. The sequences pETV4-EGFP, pSurvivin-EGFP, and pTP53-EGFP are all sequences mentioned and protected in this patent. The 5' and 3' ends of these fragments were fitted with overlapping sequences, which are identical to the sequences at which the free ends of the linearized vector were annealed at 50 degrees Celsius. Subsequently, the vector and DNA fragment were ligated using the ClonExpress II One Step Cloning Kit from Nanjing Novizan Biotechnology Co., Ltd., and the ligation product was transformed into DH5α competent bacteria. First-generation sequencing was used to verify whether the positive clone sequence matched the above sequence. Finally, pCDH-pETV4-EGFP, pCDH-pSurvivin-EGFP, and pCDH-pTP53-EGFP plasmids were successfully constructed. Plasmid diagrams and schematics are shown below. Figure 1A , 1BAs shown in Figures 1C and 1C, the plasmid and the viral packaging helper plasmids psPAX2 and pMD2.G were co-transfected into 293T cell lines. The resulting cells were collected, concentrated, and purified to obtain three recombinant lentiviruses. These three recombinant lentiviruses were then used to infect bladder cancer cell lines UM-UC-3 and T24, and normal bladder epithelial cell line SV-HUC-1, respectively. Stable transfected cell lines were obtained after drug screening. EGFP expression in the stable transfected cell lines was observed using an inverted fluorescence microscope.

[0332] Test results as follows Figure 1D As shown, the artificial promoters pETV4 and pSurvivin were activated in bladder cancer cell lines UM-UC-3 and T24, but not in the normal bladder epithelial cell line SV-HUC-1; pTP53 was not activated in bladder cancer cell lines UM-UC-3 and T24, but was activated in the normal bladder epithelial cell line SV-HUC-1. The experimental results indicate that the artificial promoter combination of pETV4, pSurvivin, and pTP53 can distinguish between normal cells and tumor cells.

[0333] Example 2: Construct a three-input logic gate system to implement the "AAND B NOT C" logic operation mode.

[0334] In this embodiment, the three-input logic gate system components Gal4-int1, int2-VP64-NLS-FUS, int2-KRAB-NLS and the effector component UAS-EGFP were transiently transferred into the tool cell line 293T. The expression of EGFP in the transiently transferred cell line was detected by flow cytometry, thereby verifying the "A AND B NOT C" logic operation mode of the three-input logic gate system.

[0335] Experimental methods:

[0336] 1. The culture method for human embryonic kidney cell line 293T is the same as in Example 1.

[0337] 2. The plasmid backbone was the pCDH plasmid, carrying an mCherry-labeled fluorescent protein and an ampicillin resistance gene, derived from Guangzhou Aiji Biotechnology Co., Ltd. The pCDH plasmid was linearized by digestion with restriction endonucleases EcoRI and NotI. DNA fragments containing the sequences Gal4-int1, int2-VP64-NLS-FUS, int2-KRAB-NLS, and UAS-EGFP were synthesized de novo, with overlapping sequences at the 5' and 3' ends. These overlapping sequences were identical to the sequences at the 3' and 5' free ends of the linearized vector, annealed at 50°C. Subsequently, the vector and DNA fragment were ligated using the ClonExpress II One Step Cloning Kit from Nanjing Novizan Biotechnology Co., Ltd., and the ligation product was transformed into DH5α competent bacteria. First-generation sequencing confirmed that the positive clone sequence was consistent with the above sequence. Finally, the plasmids pCDH-Gal4-int1, pCDH-int2-VP64-NLS-FUS, pCDH-int2-KRAB-NLS, and pCDH-UAS-EGFP were successfully constructed, as shown below... Figure 2A , 2B Figures 2C and 2D are shown. The Gal4-int1, int2-VP64-NLS-FUS, int2-KRAB-NLS, and UAS-EGFP sequences are all sequences mentioned and protected in this patent. Eight combinations of the four plasmids were obtained and transiently transfected into 293T cells. After 48 hours, the EGFP expression level in the transiently transfected cell lines was quantified by flow cytometry. The results are as follows... Figure 2E The results showed that downstream effector protein EGFP was only activated and expressed when Gal4-int1 and int2-VP64-NLS-FUS were simultaneously transiently transfected into cells, while int2-KRAB-NLS was not transiently transfected into cells; and the addition of the phase-separating domain FUS further enhanced the activation effect. The logical operation mode of the three-input logic gate system is "A AND B NOT C", such as... Figure 2F As shown.

[0338] Example 3: The gene circuit of this application can target tumor cells to activate NT-GSDMD expression, thereby inducing tumor cell pyroptosis.

[0339] In this embodiment, the N-terminus (NT-GSDMD) of the GSDMD protein was first screened to show the best effect in inducing pyroptosis, and therefore the pyroptosis-inducing effector UAS-NT-GSDMD was constructed. Next, normal epithelial cell lines and tumor cells were successively transfected with recombinant lentiviruses carrying pETV4-Gal4-int1, pSurvivin-int2-VP64-NLS-FUS, pTP53-int2-KRAB-NLS, and UAS-NT-GSDMD to construct stable cell lines with complete gene circuitry. Flow cytometry results showed that the gene circuitry of this application can target tumor cells to activate NT-GSDMD expression, thereby inducing tumor cell pyroptosis.

[0340] Experimental methods:

[0341] 1. The culture methods for bladder cancer cell lines UM-UC-3 and T24, normal bladder epithelial cell line SV-HUC-1, and human embryonic kidney cell line 293T were the same as in Example 1. Breast cancer cell line MDA-MB-231 and melanoma cell line A375 were purchased from the American Type Culture Collection (ATCC). Both MDA-MB-231 and A375 were cultured in DMEM medium containing 10% fetal bovine serum, 50 U / ml penicillin, and 50 μg / ml streptomycin.

[0342] 2. The plasmid backbone was the pCDH plasmid, carrying an mCherry-labeled fluorescent protein and an ampicillin resistance gene, derived from Guangzhou Aiji Biotechnology Co., Ltd. The pCDH plasmid was linearized by digestion with restriction endonucleases EcoRI and NotI. DNA fragments containing the N-terminal sequences of the proteins GSDMA, GSDMB1, GSDMB2, GSDMB3, GSDMB4, GSDMB5, GSDMC, GSDMD, and GSDME were synthesized de novo. The 5' and 3' ends of these fragments were then fitted with overlapping sequences identical to those annealed at 50°C to the free ends of the linearized vector. Subsequently, the vector and DNA fragment were ligated using the ClonExpress II One Step Cloning Kit from Nanjing Novizan Biotechnology Co., Ltd., and the ligation product was transformed into DH5α competent bacteria. First-generation sequencing was used to verify whether the positive clone sequences were consistent with the above sequences. Finally, the plasmids pCDH-NT-GSDMA, pCDH-NT-GSDMB1, pCDH-NT-GSDMB2, pCDH-NT-GSDMB3, pCDH-NT-GSDMB4, pCDH-NT-GSDMB5, pCDH-NT-GSDMC, pCDH-NT-GSDMD, and pCDH-NT-GSDME were successfully constructed. These plasmids were transiently transfected into 293T cells, and the proportion of propidium iodide (PI)-positive cells was detected by flow cytometry after 48 hours. Figure 3A As shown, the N-terminus (NT-GSDMD) of the GSDMD protein has the best effect in inducing pyroptosis, and therefore it is used as the effector protein of the gene circuit in this application.

[0343] 3. The plasmid backbone was the pCDH plasmid, carrying an mCherry-labeled fluorescent protein and an ampicillin resistance gene, sourced from Guangzhou Aiji Biotechnology Co., Ltd. The pCDH plasmid was linearized by digestion with restriction endonucleases EcoRI and NotI. DNA fragments containing the sequences Rabbit globin poly A-NLS-KRAB-int2-pTP53-hGH poly(A)signal-int1-Gal4-pETV4-pSurvivin-int2-VP64-NLS-FUS-Tm.synth.20 (named according to the gene circuit element arrangement order in the 5'LTR-3'LTR direction of the pCDH vector) and UAS-NT-GSDMD were synthesized de novo. The 5' and 3' ends of these fragments were then fitted with overlapping sequences identical to those annealed at 50°C to the free ends of the linearized vector. Subsequently, the vector and DNA fragment were ligated using the ClonExpress II One Step Cloning Kit from Nanjing Novizan Biotechnology Co., Ltd., and the ligation product was transformed into DH5α competent bacteria. First-generation sequencing was used to verify whether the positive clone sequence was consistent with the above sequence. Finally, pCDH-Rabbit globin poly A-NLS-KRAB-int2-pTP53-hGH poly(A)signal-int1-Gal4-pETV4-pSurvivin-int2-VP64-NLS-FUS-Tm.synth.20 (plasmid 1) and pCDH-UAS-NT-GSDMD (plasmid 2) were successfully constructed. The schematic diagrams and plasmid images of plasmids 1 and 2 are shown below. Figure 3B , 3C and Figure 3B , 3DAs shown. The sequences Rabbit globin poly A, pTP53-int2-KRAB-NLS, hGH poly(A)signal, pETV4-Gal4-int1, pSurvivin-int2-VP64-NLS-FUS, Tm.synth.20, and UAS-NT-GSDMD are all sequences mentioned and protected in this patent. Plasmid 1, plasmid 2, and the vector virus packaging helper plasmids psPAX2 and pMD2.G were co-transfected into 293T cell lines, and the corresponding recombinant lentivirus 1 and recombinant lentivirus 2 were collected, concentrated, and purified. Recombinant lentivirus 1 was used to infect normal bladder epithelial cell line SV-HUC1, bladder cancer cell lines UM-UC-3 and T24, breast cancer cell line MDA-MB-231, and melanoma cell line A375, respectively. After drug screening, stable transfected cells were obtained for each cell type. The above stable transfected cells were further infected with recombinant lentivirus 2, and PI staining was performed after 48 hours. The proportion of PI-positive cells was detected by flow cytometry. Figure 3E As shown, the gene circuit of this application can target and induce pyroptosis in tumor cell lines UM-UC-3, T24, MDA-MB-231 and A375, without inducing pyroptosis in normal bladder epithelial cell line SV-HUC-1, and has the function of specifically inducing pyroptosis in tumor cells.

[0344] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. An artificial promoter capable of distinguishing normal cells from tumor cells, characterized in that: The artificial promoter includes at least one of pETV4, pSurvivin and pTP53; the sequence of pETV4 is shown as SEQ ID NO:2, the sequence of pSurvivin is shown as SEQ ID NO:3, and the sequence of pTP53 is shown as SEQ ID NO:

4.

2. A gene that can distinguish normal cells from tumor cells, characterized in that: The gene includes at least one of the pETV4-EGFP gene, the pSurvivin-EGFP gene and the pTP53-EGFP gene; the sequence of the pETV4-EGFP gene is shown in SEQ ID NO:5, the sequence of the pSurvivin-EGFP gene is shown in SEQ ID NO:6, and the sequence of the pTP53-EGFP gene is shown in SEQ ID NO:

7.

3. A recombinant vector capable of distinguishing normal cells from tumor cells, characterized in that: The recombinant vector comprises at least one of a recombinant plasmid containing a pETV4-EGFP gene, a recombinant plasmid containing a pSurvivin-EGFP gene, and a recombinant plasmid containing a pTP53-EGFP gene, wherein the sequence of the pETV4-EGFP gene is shown in SEQ ID NO: 5, the sequence of the pSurvivin-EGFP gene is shown in SEQ ID NO: 6, and the sequence of the pTP53-EGFP gene is shown in SEQ ID NO:

7. Preferably, the basic vectors of the recombinant plasmid containing the pETV4-EGFP gene, the recombinant plasmid containing the pSurvivin-EGFP gene, and the recombinant plasmid containing the pTP53-EGFP gene are viral vectors, respectively.

4. A recombinant virus capable of distinguishing normal cells from tumor cells, characterized in that: The recombinant virus is a packaging body obtained by co-transfecting the recombinant vector as claimed in claim 3 with an auxiliary packaging plasmid into a host cell; preferably, the host cell is a 293T cell.

5. Use of the artificial promoter according to claim 1, the gene according to claim 2, the recombinant vector according to claim 3, or the recombinant virus according to claim 4 in preparing a reagent or a kit for distinguishing normal cells from tumor cells.

6. A gene that recognizes tumor cells and induces their pyroptosis, characterized in that: The genes include pETV4-Gal4-int1 gene, pSurvivin-int2-VP64-NLS-FUS gene, pTP53-int2-KRAB-NLS gene and UAS-NT-GSDM gene; the sequences of the pETV4-Gal4-int1 gene, pSurvivin-int2-VP64-NLS-FUS gene and pTP53-int2-KRAB-NLS gene are shown in SEQ ID NO:12, SEQ ID NO:21 and SEQ ID NO:25, respectively; preferably, the sequence of the NT-GSDM gene in the UAS-NT-GSDM gene is shown in SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40; more preferably, the UAS-NT-GSDM gene is the UAS-NT-GSDMD gene, and the sequence of the UAS-NT-GSDMD gene is shown in SEQ ID NO:

41.

7. A recombinant vector for recognizing tumor cells and inducing pyroptosis thereof, characterized in that: The recombinant vector includes a recombinant plasmid 1 containing a pETV4-Gal4-int1 gene, a pSurvivin-int2-VP64-NLS-FUS gene and a pTP53-int2-KRAB-NLS gene, and a recombinant plasmid 2 containing a UAS-NT-GSDM gene; the sequences of the pETV4-Gal4-int1 gene, the pSurvivin-int2-VP64-NLS-FUS gene and the pTP53-int2-KRAB-NLS gene are shown in SEQ ID NO: 12, SEQ ID NO: 21, and SEQ ID NO: 25, respectively; preferably, the sequence of the NT-GSDM gene in the UAS-NT-GSDM gene is shown in SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 or SEQ ID NO:40; more preferably, the UAS-NT-GSDM gene is the UAS-NT-GSDMD gene, the sequence of the UAS-NT-GSDMD gene is shown in SEQ ID NO:41, and the basic vectors of the recombinant plasmid 1 and the recombinant plasmid 2 are respectively viral vectors.

8. A recombinant virus that recognizes tumor cells and induces pyroptosis, characterized in that: The recombinant virus is a packaging body obtained by co-transfecting the recombinant vector as claimed in claim 7 with an auxiliary packaging plasmid into a host cell.

9. The recombinant virus according to claim 8, characterized in that The host cell is a 293T cell, and the auxiliary packaging plasmid includes psPAX2 and pMD2.G.

10. Use of the artificial promoter according to claim 1, the gene according to claim 6, the recombinant vector according to claim 7 or the recombinant virus according to claim 8 or 9 in the preparation of a drug for recognizing tumor cells and inducing pyroptosis thereof.

Citation Information

Patent Citations

  • Tumor distinctive embedment promoter, constructing method and application thereof

    CN101649319A

  • Enhanced tumor-specific therapy vector

    CN102618577A

  • Synthetic gene network system with specificity and sensitivity for treating malignant tumors

    CN116059405A

  • Progression elevated gene-3 and uses thereof

    US20010014734A1

  • Programmable Oncolytic Virus Vaccine System and Method

    US20200017881A1